Practical Dermatology

CuralysMD announced the unveiling of a new over-the-counter eczema skin protectant lotion designed to support skin barrier repair in patients with mild to moderate eczema. The steroid-free formulation contains colloidal oatmeal 1% (USP) along with the company's proprietary SMRTActiv™ technology. According to the company, the lotion is intended to help calm irritated skin while supporting barrier function and can be used either as a standalone moisturizer or alongside prescription eczema therapies.

LEO Pharma has announced positive topline results from the Phase 2 TRAPEDS-1 trial evaluating the pharmacokinetics and long-term safety of tralokinumab in children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD). According to the company, the study met its primary objective, demonstrating a pharmacokinetic profile consistent with previous findings for tralokinumab and a safety profile that remained consistent throughout long-term follow-up.

Private equity investment in dermatology continues at a rapid pace in 2026, with buyer demand remaining strong despite more than a decade of consolidation across the specialty, according to a new market update from Physician Growth Partners. Although consolidation began accelerating around 2014, the report notes that most dermatology practices remain independently owned.

A multidisciplinary panel of experts has developed consensus recommendations to help standardize staging and surveillance imaging for patients with localized cutaneous squamous cell carcinoma (cSCC), publishing the recommendations online in JAMA Dermatology.

The US Food and Drug Administration (FDA) anounced that it has accepted Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) seeking to expand the indication for ZORYVE (roflumilast) cream 0.05% to include infants aged 3 to 24 months with mild to moderate atopic dermatitis (AD) The application was supported by data from the Phase 2 open-label INTEGUMENT-INFANT trial and a Phase 1 open-label pharmacokinetic study evaluating once-daily roflumilast cream 0.05% in infants younger...

Teva Pharmaceutical Industries Ltd. has announced plans to advance its investigational anti-interleukin-15 (IL-15) monoclonal antibody (TEV-'408) into a Phase 2b clinical trial for non-segmental vitiligo (NSV) in the fourth quarter of 2026 following encouraging interim Phase 1b results. TEV-'408 is a Teva-discovered biologic designed to inhibit IL-15, a cytokine implicated in the persistence of autoreactive memory T cells believed to drive vitiligo pathogenesis.

A phase III study published in the Journal of the American Academy of Dermatology found that picankibart, an investigational interleukin (IL)-23p19 inhibitor, produced high rates of skin clearance with durable efficacy through 52 weeks in adults with moderate-to-severe plaque psoriasis.

The redesign of laboratory packaging to reduce plastic waste is a feasible near-term strategy for reducing plastic waste in skin-model research without disrupting validated experimental systems, according to a commentary in the Journal of Investigative Dermatology. The authors noted that modern skin-model research depends heavily on sterile, single-use plastics for keratinocyte and fibroblast cultures, reconstructed human epidermis, skin equivalents, and organ-on-chip systems.

Children and adolescents with moderate-to-severe atopic dermatitis (AD) maintained improvements in disease signs and symptoms during 1 year of dupilumab treatment, according to a post hoc analysis of the ongoing phase 3 LIBERTY AD PED-OLE open-label extension study. The findings were published in the British Journal of Dermatology.

Laser speckle imaging (LSI) may offer an objective, noninvasive method for assessing rosacea severity while improving differentiation from other inflammatory facial dermatoses, according to findings published in Archives of Dermatological Research. Study authors enrolled 37 patients with rosacea and 38 patients with other facial dermatoses.